Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to engineer a tri-specific antibody-based molecule that sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Warmuth, Stefan, Gunde, Tea, Snell, Daniel, Brock, Matthias, Weinert, Christopher, Simonin, Alexandre, Hess, Christian, Tietz, Julia, Johansson, Maria, Spiga, Fabio Mario, Heiz, Robin, Flückiger, Naomi, Wagen, Sandro, Zeberer, Julia, Diem, Dania, Mahler, Dana, Wickihalder, Belinda, Muntwiler, Simone, Chatterjee, Bithi, Küttner, Benjamin, Bommer, Bettina, Yaman, Yasemin, Lichtlen, Peter, Urech, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278964/
https://www.ncbi.nlm.nih.gov/pubmed/35844969
http://dx.doi.org/10.1080/2162402X.2021.2004661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278964/
https://www.ncbi.nlm.nih.gov/pubmed/35844969
http://dx.doi.org/10.1080/2162402X.2021.2004661

Ejemplares similares